A Mississippi overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
40.4% of Mississippi adults have obesity, per CDC BRFSS 2024 data 1. That is the second-highest rate of all 50 states and D.C., trailing only West Virginia's 41.4%, and about 7.3 points above the 33.1% U.S. rate 2.
Roughly two in five Mississippi adults live with obesity. Mississippi is also, unusually, a state where Medicaid says yes.
Yes, and that puts Mississippi in a minority nationally. Mississippi Medicaid affirmatively covers GLP-1 and other anti-obesity medications for the treatment of obesity itself, not only for diabetes: many states instead use the Social Security Act's optional exclusion to leave weight-loss drugs off their formularies entirely.
Effective July 1, 2026, the Division of Medicaid's Universal Preferred Drug List lists Saxenda (liraglutide) and Wegovy (semaglutide) as preferred for enrollees age 12 and older, and Foundayo (orforglipron) and Zepbound (tirzepatide) as preferred for adults 18 and older; Xenical (orlistat) is non-preferred 4.
Every one of these requires prior authorization 3. Adults need a BMI of 30 or higher, or 27–29.9 plus a qualifying condition such as hypertension, high cholesterol, pre-diabetes, sleep apnea, cardiovascular disease, or fatty liver disease; adolescents qualify through separate weight- and BMI-percentile criteria. Only one anti-obesity medication is covered at a time, a documented diet-and-activity plan is required, and annual renewal requires at least nine pharmacy claims in the past year plus either 5% weight loss or a maintained BMI reduction. Contrave, Qsymia, phentermine, and use during pregnancy or breastfeeding are excluded outright 3.
This is coverage for Mississippi Medicaid, MSCAN, and MSCHIP enrollees specifically. It is separate from, and has no bearing on, Astra's national cash-pay pricing.
Our price in Mississippi is the same as our price everywhere else: $68/month for semaglutide, $118/month for tirzepatide, both on 12-month plans ($816 / $1,416 billed annually), the same price at every dose.
That flat, posted, dose-independent structure matters more here than in most states. Mississippi's median household income is $59,127 (ACS 2024 1-year estimate) 6, the lowest or near-lowest of any state we serve. A price that escalates as your dose escalates is a budgeting problem; a price that does not, is not.
For anyone who does not qualify for Medicaid or whose prior authorization is denied, that posted number is the whole offer.
Telehealth prescribing of non-controlled medications such as semaglutide and tirzepatide is broadly permitted for licensed providers treating patients located in Mississippi, subject to the same standard of care that applies to in-person visits.
As in every state, the separate question of compounded versions of these drugs is governed federally by FDA's Section 503A framework: since FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, a compounding pharmacy may generally prepare a compounded copy of an FDA-approved GLP-1 only for an individual patient whose prescriber documents a clinically significant difference from the approved product, and FDA advises against compounding with salt forms such as semaglutide sodium or acetate.
TODO — Mississippi's specific telehealth-practice statute and the Mississippi State Board of Pharmacy's compounding-specific guidance have not been verified in this pass. Nothing beyond the federal frame above is asserted here. Regulators to check: the Mississippi State Board of Medical Licensure (msbml.ms.gov) and the Mississippi State Board of Pharmacy (mbp.ms.gov).
Astra serves patients in all 50 states, Mississippi included, across a population of 2,943,045 5. Mississippi residents can start today: intake, prescription, and refills are handled online, with medication from a state-licensed US compounding pharmacy.
See how these numbers play out in Jackson, Mississippi's capital and largest city, on the page below.
Astra treats patients in Mississippi through state-licensed physicians.
See how these numbers play out in Jackson, Mississippi's capital and largest city.
Yes — an important exception nationally. Effective July 1, 2026, Mississippi Medicaid covers Wegovy (semaglutide) and Saxenda (liraglutide) as preferred agents for obesity itself, not just diabetes, for enrollees 12 and up; Zepbound (tirzepatide) and Foundayo (orforglipron) are preferred for adults 18+. Coverage requires prior authorization — a BMI of 30+, or 27–29.9 with a qualifying condition such as high blood pressure or pre-diabetes — a documented diet-and-activity plan, and annual reauthorization showing adherence and continued progress. Only one anti-obesity medication is covered at a time. This is Medicaid coverage for Medicaid, MSCAN, and MSCHIP enrollees only — it has no bearing on Astra's cash-pay pricing.
No — and that's deliberate. Astra is a telehealth provider, not a local clinic, so the price is identical everywhere: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There's no Mississippi discount, and no in-state markup either. In a state with one of the lowest median household incomes in the country, we think a flat, dose-independent national price is the most honest thing we can show — not a dose-ladder price that climbs as treatment works.
For Mississippi Medicaid enrollees who qualify, Medicaid should usually be the first call — it's a covered benefit, not a monthly cash decision. Astra exists for everyone else: Mississippians without Medicaid, those whose income or plan doesn't qualify them, those who don't clear the BMI-plus-comorbidity prior-authorization bar, and those who've already used their one covered anti-obesity agent and want a different option. Telehealth also starts faster than a Medicaid prior-authorization cycle, with no annual reauthorization tied to pharmacy-claims adherence.
No. Astra visits are conducted online by providers licensed to treat Mississippi patients, held to the same standard of care as an in-person visit. [TODO: cite Mississippi's specific telehealth-practice-establishment statute here before publish — not yet verified this session; do not assert a rule beyond the general federal/telehealth frame until it is.]
Only under narrow federal conditions, and there are no guarantees. Since FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, a licensed pharmacy may generally compound a copy of an FDA-approved GLP-1 only for an individual patient whose prescriber documents a clinically significant difference from the approved product — and FDA advises against compounding with salt forms such as semaglutide sodium or acetate. [TODO: add Mississippi State Board of Pharmacy's specific compounding guidance, if any, before publish.]
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.